$11.38
0.010.09%
At Close: -
$11.38
00.00%
After Hours: 1:01 PM EDT
15 minutes delayed
Y-mAbs Therapeutics
YMABNASDAQ
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock, Analyst Ratings, Price Targets, Predictions
Y-mAbs Therapeutics Inc has a consensus price target of $14.33, established from looking at the 36 latest analyst ratings. The last 3 analyst ratings were released from Truist Securities, HC Wainwright & Co., and HC Wainwright & Co. on June 28, 2024, May 13, 2024, and March 6, 2024. With an average price target of $21.67 between Truist Securities, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 90.39% upside for Y-mAbs Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
HC Wainwright & Co.
Canaccord Genuity
BMO Capital
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Y-mAbs Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/28/2024 | Buy Now | 84.53% | Truist Securities | Nicole Germino | → $21 | Initiates | → Buy | Get Alert |
| 05/13/2024 | Buy Now | 93.32% | HC Wainwright & Co. | Robert Burns | $21 → $22 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | 93.32% | HC Wainwright & Co. | Robert Burns | — | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | 128.47% | Canaccord Genuity | Bill Maughan | $22 → $26 | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | 128.47% | BMO Capital | Etzer Darout | $16 → $26 | Maintains | Outperform | Get Alert |
| 02/20/2024 | Buy Now | 84.53% | HC Wainwright & Co. | Robert Burns | $11 → $21 | Maintains | Buy | Get Alert |
| 11/15/2023 | Buy Now | -3.34% | HC Wainwright & Co. | Robert Burns | → $11 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2023 | Buy Now | -38.49% | JP Morgan | Tessa Romero | $8 → $7 | Maintains | Underweight | Get Alert |
| 08/14/2023 | Buy Now | -56.06% | Morgan Stanley | Michael Ulz | $7 → $5 | Maintains | Underweight | Get Alert |
| 08/14/2023 | Buy Now | -3.34% | HC Wainwright & Co. | Robert Burns | → $11 | Reiterates | Buy → Buy | Get Alert |
| 07/25/2023 | Buy Now | 93.32% | Canaccord Genuity | William Plovanic | $21 → $22 | Maintains | Buy | Get Alert |
| 06/07/2023 | Buy Now | 84.53% | Canaccord Genuity | William Plovanic | → $21 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | 5.45% | B of A Securities | Alec Stranahan | $6 → $12 | Maintains | Neutral | Get Alert |
| 05/10/2023 | Buy Now | -38.49% | Morgan Stanley | Michael Ulz | $4 → $7 | Maintains | Underweight | Get Alert |
| 05/10/2023 | Buy Now | 14.24% | Wedbush | David Nierengarten | $5 → $13 | Upgrade | Neutral → Outperform | Get Alert |
| 05/09/2023 | Buy Now | 84.53% | Canaccord Genuity | William Plovanic | $18 → $21 | Maintains | Buy | Get Alert |
| 04/04/2023 | Buy Now | -3.34% | HC Wainwright & Co. | Robert Burns | $19 → $11 | Maintains | Buy | Get Alert |
| 04/03/2023 | Buy Now | — | Guggenheim | Etzer Darout | — | Downgrade | Buy → Neutral | Get Alert |
| 04/01/2023 | Buy Now | -47.28% | B of A Securities | Alec Stranahan | → $6 | Maintains | Neutral | Get Alert |
| 03/31/2023 | Buy Now | 58.17% | Canaccord Genuity | William Maughan | $20 → $18 | Maintains | Buy | Get Alert |
| 01/30/2023 | Buy Now | 14.24% | BMO Capital | Etzer Darout | $12 → $13 | Maintains | Outperform | Get Alert |
| 01/27/2023 | Buy Now | — | Morgan Stanley | Michael Ulz | — | Downgrade | Equal-Weight → Underweight | Get Alert |
| 01/05/2023 | Buy Now | — | Cowen & Co. | Joseph Thome | — | Downgrade | Outperform → Market Perform | Get Alert |
| 12/15/2022 | Buy Now | -47.28% | B of A Securities | Alec Stranahan | $5 → $6 | Maintains | Neutral | Get Alert |
| 12/02/2022 | Buy Now | -56.06% | B of A Securities | Alec Stranahan | $23 → $5 | Downgrade | Buy → Neutral | Get Alert |
| 11/01/2022 | Buy Now | 5.45% | BMO Capital | Etzer Darout | $29 → $12 | Maintains | Outperform | Get Alert |
| 10/31/2022 | Buy Now | 137.26% | Canaccord Genuity | William Maughan | $35 → $27 | Maintains | Buy | Get Alert |
| 10/31/2022 | Buy Now | -29.7% | Morgan Stanley | Michael Ulz | $17 → $8 | Maintains | Equal-Weight | Get Alert |
| 10/31/2022 | Buy Now | -47.28% | Wedbush | David Nierengarten | → $6 | Downgrade | Outperform → Neutral | Get Alert |
| 10/31/2022 | Buy Now | 66.96% | HC Wainwright & Co. | Robert Burns | $63 → $19 | Maintains | Buy | Get Alert |
| 10/31/2022 | Buy Now | -38.49% | JP Morgan | Tessa Romero | $16 → $7 | Downgrade | Neutral → Underweight | Get Alert |
| 09/09/2022 | Buy Now | 49.38% | Morgan Stanley | Michael Ulz | $15 → $17 | Maintains | Equal-Weight | Get Alert |
| 06/24/2022 | Buy Now | 137.26% | BMO Capital | Etzer Darout | → $27 | Initiates | → Outperform | Get Alert |
| 02/28/2022 | Buy Now | 453.6% | HC Wainwright & Co. | Robert Burns | $68 → $63 | Maintains | Buy | Get Alert |
| 01/03/2022 | Buy Now | 137.26% | JP Morgan | Tessa Romero | $30 → $27 | Maintains | Neutral | Get Alert |
| 11/16/2021 | Buy Now | 163.62% | JP Morgan | Tessa Romero | — | Downgrade | Overweight → Neutral | Get Alert |
FAQ
What is the target price for Y-mAbs Therapeutics (YMAB) stock?
The latest price target for Y-mAbs Therapeutics (NASDAQ:YMAB) was reported by Truist Securities on June 28, 2024. The analyst firm set a price target for $21.00 expecting YMAB to rise to within 12 months (a possible 84.53% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Y-mAbs Therapeutics (YMAB)?
The latest analyst rating for Y-mAbs Therapeutics (NASDAQ:YMAB) was provided by Truist Securities, and Y-mAbs Therapeutics initiated their buy rating.
When was the last upgrade for Y-mAbs Therapeutics (YMAB)?
The last upgrade for Y-mAbs Therapeutics Inc happened on May 10, 2023 when Wedbush raised their price target to $13. Wedbush previously had a neutral for Y-mAbs Therapeutics Inc.
When was the last downgrade for Y-mAbs Therapeutics (YMAB)?
The last downgrade for Y-mAbs Therapeutics Inc happened on April 3, 2023 when Guggenheim changed their price target from N/A to N/A for Y-mAbs Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Y-mAbs Therapeutics (YMAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Y-mAbs Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Y-mAbs Therapeutics was filed on June 28, 2024 so you should expect the next rating to be made available sometime around June 28, 2025.
Is the Analyst Rating Y-mAbs Therapeutics (YMAB) correct?
While ratings are subjective and will change, the latest Y-mAbs Therapeutics (YMAB) rating was a initiated with a price target of $0.00 to $21.00. The current price Y-mAbs Therapeutics (YMAB) is trading at is $11.38, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.